Literature DB >> 12169586

Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia.

Thomas A Russo1, Lori A Bartholomew, Bruce A Davidson, Jadwiga D Helinski, Ulrike B Carlino, Paul R Knight, Michael F Beers, Elena N Atochina, Robert H Notter, Bruce A Holm.   

Abstract

An in vivo rat model was used to evaluate the effects of Escherichia coli pneumonia on lung function and surfactant in bronchoalveolar lavage (BAL). Total extracellular surfactant was increased in infected rats compared with controls. BAL phospholipid content in infected rats correlated with the severity of alveolar-capillary leak as reflected in lavage protein levels (R(2) = 0.908, P < 0.0001). Western blotting showed that levels of surfactant protein (SP)-A and SP-D in BAL were significantly increased in both large and small aggregate fractions at 2 and 6 h postinstillation of E. coli. SP-B was also increased at these times in the large aggregate fraction of BAL, whereas SP-C levels were increased at 2 h and decreased at 6 h relative to controls. The small-to-large (S/L) aggregate ratio (a marker inversely proportional to surfactant function) was increased in infected rats with >50 mg total BAL protein. There was a significant correlation (R(2) = 0.885, P < 0.0001) between increasing S/L ratio in BAL and pulmonary damage assessed by total protein. Pulmonary volumes, compliance, and oxygen exchange were significantly decreased in infected rats with >50 mg of total BAL protein, consistent with surfactant dysfunction. In vitro surface cycling studies with calf lung surfactant extract suggested that bacterially derived factors may have contributed in part to the surfactant alterations seen in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169586     DOI: 10.1152/ajplung.00071.2002

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  10 in total

1.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

Review 2.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

3.  Surfactant protein D interacts with alpha2-macroglobulin and increases its innate immune potential.

Authors:  Hayley A Craig-Barnes; Barbara S Doumouras; Nades Palaniyar
Journal:  J Biol Chem       Date:  2010-03-05       Impact factor: 5.157

4.  Requirement for Serratia marcescens cytolysin in a murine model of hemorrhagic pneumonia.

Authors:  Norberto González-Juarbe; Chris A Mares; Cecilia A Hinojosa; Jorge L Medina; Angelene Cantwell; Peter H Dube; Carlos J Orihuela; Molly A Bergman
Journal:  Infect Immun       Date:  2014-11-24       Impact factor: 3.441

5.  Extraintestinal pathogenic Escherichia coli survives within neutrophils.

Authors:  Helen Nazareth; Stacy A Genagon; Thomas A Russo
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

6.  Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Ulrike MacDonald; Nicole R Luke; Steven R Gill; Anthony A Campagnari
Journal:  Infect Immun       Date:  2008-06-09       Impact factor: 3.441

Review 7.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

8.  Fetal and neonatal samples of a precursor surfactant protein B inversely related to gestational age.

Authors:  Christoph Czernik; Gerd Schmalisch; Christoph Bührer; Hans Proquitté
Journal:  BMC Pediatr       Date:  2013-10-10       Impact factor: 2.125

9.  Inhibition of pulmonary nuclear factor kappa-B decreases the severity of acute Escherichia coli pneumonia but worsens prolonged pneumonia.

Authors:  James Devaney; Gerard F Curley; Mairead Hayes; Claire Masterson; Bilal Ansari; Timothy O'Brien; Daniel O'Toole; John G Laffey
Journal:  Crit Care       Date:  2013-04-27       Impact factor: 9.097

10.  Remote ischemic preconditioning attenuates cardiopulmonary bypass-induced lung injury.

Authors:  Xiaona Zhou; Runzhu Jiang; Yucai Dong; Lifeng Wang
Journal:  PLoS One       Date:  2017-12-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.